Conference Coverage

Tool predicts lymphoma, death in primary Sjögren’s syndrome patients


 

FROM THE EULAR CONGRESS 2014

Since the analysis of these 921 patients was completed in January 2013, an additional 124 patients with primary SS have joined the cohort. In this larger cohort, baseline ESDAI score of 14 or higher and presence of more than one laboratory marker (lymphopenia, low cryoglobulins, hypocomplementemia, and monoclonal band) both were significantly associated with SS-related death.

Dr. Brito Zerón noted that the investigators have not analyzed whether treatment influenced outcomes in the cohort, but they plan to.

The investigators had no financial disclosures.

Pages

Recommended Reading

Different triggers found for knee and hand OA
MDedge Internal Medicine
Sarilumab shown safe, effective for RA in phase III trial
MDedge Internal Medicine
International RA risk tool for CVD comes closer to reality
MDedge Internal Medicine
Gut inflammation linked to worsening spondyloarthritis
MDedge Internal Medicine
Tofacitinib bests methotrexate for RA
MDedge Internal Medicine
FVC inadequate when assessing scleroderma lung disease
MDedge Internal Medicine
Stem-cell transplants growing routine for severe scleroderma
MDedge Internal Medicine
VIDEO: Gene profiling could signal start of personalized medicine in RA
MDedge Internal Medicine
Higher risk of death seen with oral steroids in RA interstitial lung disease
MDedge Internal Medicine
Giant-cell arteritis patients face high aortic aneurysm dissection risk
MDedge Internal Medicine